21
both presence and absence of variants provide valuable dosing information. 3; 4 The frequencies 48 of many pharmacogenetic alleles vary greatly by global population, meaning that people with 49 different ancestries can have considerably different likelihoods of carrying an allele that is 50 associated with a particular drug response. For example, the CYP3A5*3 allele has been found at 51 a frequency of 98% in an Iranian population but at 11% in a Ngoni population from Malawi. 5; 6 52 A single value for global allele frequency would fail to reflect this pattern. Presenting the 53 differences in frequencies of pharmacogenetic alleles is important for communicating the scale 54 of their expected impact on drug response and the degree of variation between populations. This 55 information is invaluable for furthering pharmacogenetic research and implementation. 56
Many pharmacogenetic studies present allelic data for very specific populations, such as 57 from a single country or ethnic group, which are difficult to incorporate into broader research or 58 implementation. Literature curation and gene summaries, such as those from the 59 Pharmacogenomics Knowledgebase (PharmGKB: www.pharmgkb.org), must group these 60 specific populations when annotating pharmacogenetic studies to allow users to easily compare 61 information from multiple studies. As such, tagging studies with population group identifiers is 62 an important component of knowledge extraction from curated literature. These population group 63 labels then are used in aggregating and evaluating overall evidence for gene-drug associations, 64 which eventually inform clinical implementation guidelines, such as those of the Clinical 65
Pharmacogenetics Implementation Consortium (CPIC: www.cpicpgx.org). 66 4 Current methods for grouping global populations in pharmacogenetics are based on 67 subjective, vague, and inconsistent geographical boundaries, or on populations that are 68 geographically straightforward to cluster and reflect little admixture. [7] [8] [9] [10] [11] As an example of the 69 issues with current grouping methods, some studies cluster participants of Egyptian descent with 70 African populations, while others cluster them with Middle Eastern populations. 12; 13 While this 71 discrepancy illustrates inconsistencies of geographic borders, the clustering of African-descent 72 populations of the Americas with populations from Africa, as seen in the 1000 Genomes African 73 (AFR) superpopulation, provides another example of the challenges of employing a small 74 number of categories. The genetic patterns seen in American populations with African ancestry 75 differs dramatically from populations in Africa due to admixture primarily with European and 76 American Indian populations. [14] [15] [16] While sharing common ancestry, the recent admixture 77 typically observed in the Americas can complicate average allele frequency estimation or, at a 78 minimum, make these combined groupings less homogeneous. 15 These insufficient grouping 79 systems, often ad-hoc and not fully representative of what we have learned through population 80 genomic studies, create a barrier to understanding and interpreting pharmacogenetic allele 81 frequencies in a globally representative fashion. 82 Up until July 2018, PharmGKB annotated studies using the five race categories defined 83 by the US Office of Management and Budget (OMB): White, Black or African American, 84
American Indian or Alaska Native, Asian, and Native Hawaiian or Pacific Islander, with an 85 additional ethnicity OMB category of Hispanic/Latino. While PharmGKB serves as a global 86 resource, these OMB groups are US-centric and lack the capacity to truly capture the scale of 87 global human diversity. We also investigated the utility of the biogeographic categories 88 employed by the Human Genome Diversity Panel -Centre d'Etude du Polymophisme Humain 89 5 (HGDP -CEPH), which groups its 52 populations into Africa, Europe, Middle East, South and 90 Central Asia, East Asia, Oceania and the Americas. 7; 17; 18 These population labels work well for 91 the populations included in the HGDP data set, which are not located in ambiguous regions 92 between group borders and which mostly contain populations with little admixture. However, 93 papers curated at PharmGKB can include populations located all over the world, including in the 94 transitional zones between HGDP geographical regions and admixed populations. This leads to 95 ambiguity in how such populations would be grouped using HGDP categories. In conclusion, 96 existing systems are insufficient for capturing the diversity of study populations in a replicable 97 manner that is consistent with patterns of human genetic variation. 98 Therefore, we sought to define a grouping system of global populations that could be 99 used consistently to annotate pharmacogenetic studies and relevant alleles, and could capture 100 global human population genetic patterns. Using population genetics data sources, including the 101 1000 Genomes Phase 3 data release and the HGDP, we propose a simple and robust grouping 102 pattern based on nine broad biogeographic regions that represent major geographic regions of the 103 world (Figure 1) . It is important to note that classifying individuals and communities into a few 104 distinct groups with defined boundaries conflicts with our understanding of human variation, 105 history, and social/cultural identities. As a result, we respectfully present these groups as a tool 106 to represent broad differences in frequencies of genetic variation rather than as a classification 107 of human diversity. 108
We chose this geographic clustering pattern because geography has historically been the 109 greatest predictor of genetic variation between human populations, with genetic distance 110 increasing as geographic distance increases. 19 This geographic pattern aids consistency in 111 population groupings by setting boundaries along national borders. We have also included two 112 6 admixed groups due to their distinct genetic patterns compared to the geographically-defined 113 groups and because they are relatively frequently described in pharmacogenetic cohorts. Nine 114 groups were selected to be enough to illustrate the broad diversity in global allele frequencies, 115 yet small enough to apply easily and to be tractable in grouping specific populations. [20] [21] [22] [23] We 116 then used autosomal genotype data to validate the ability of these groups to capture broad genetic 117 variation and to optimally reflect global patterns. The groups are given below with their 118 abbreviations. 119 120
Geographical populations: 121
To simplify utility, geographic boundaries between groupings are drawn predominantly 122 along country borders, with only Russia divided into east and west along the Ural Mountains 123 boundary due to the large size and genetic heterogeneity of the country. We intend these groups 124 to represent peoples with a predominance of ancestors who were in the region pre-Diaspora and 125 pre-colonization. 126
American (AME): The American genetic ancestry group includes all Native, Indigenous, and 127 We include two admixed groups representing populations with recent mixing of geographically-149 based populations and therefore, have distinct genetic patterns which are not adequately reflected 150 by any single geographically-based group. While many populations reflect a degree of 151 admixture, we selected these two populations because they are frequently reported in 152 pharmacogenetic studies. Latino group, we have opted to use the abbreviation LAT for this group. This removes the 172 potential for confusion between the Latino group and the other admixed group of African 173 American/Afro-Caribbean. 174 Figure 1 illustrates the countries included in each group and removes any ambiguity of 175 the group boundaries. We intend this map to be used as a guide for grouping populations. Study 176 subjects of an ancestry that is not within the geographic cluster in which they currently live will 177 be included in the geographic cluster reflecting their ancestry. For example, South Africans of 178
Dutch descent would be included in the European cluster rather than the Sub-Saharan African 9 cluster. However, when lacking a clear description otherwise, the population will be included in 180 the group that includes its home country. This approach highlights the importance of 181 understanding and recording detailed self-identity and self-reported ethnicity in the context of 182 genetic studies. 183
To validate the genetic variability distinguished by these population groups, we 184 conducted Principal Components Analysis (PCA) of unrelated individuals from 1000 Genomes. 185
As seen in Figure 2A , the first two principal components (PCs) separate populations by 186 geographic region, especially along continental boundaries, and illustrate the increasing genetic 187 distance between populations of increasing geographic distance. As can be seen in the 188 overlapping PC distribution of individuals of different population groups, human genetic 189 diversity is a spectrum, 18 and therefore the geographic boundaries of these groups should be 190 understood as an obligatory divide to create relevant groupings, with the acknowledgement that 191 these borders are constrained by modern country borders and therefore are inherently arbitrary in 192 geographic space. 18 However, as shown in Figure 2B , only a few PCs are needed to accurately 193 predict these population clusters. Even with only 4 PCs, the minimum area under the curve 194 (AUC) for correct cluster prediction is 97.9% for most populations using multiple logistic 195 regression. The only outlier is the African American/Afro-Caribbean cluster, consistent with 196 ancestral similarity to the African cluster. 14; 27 Here still, with a larger number of PCs, the AUC 197 is above 93%, even with the observed ancestry outliers present in the 1000 Genomes African 198 Americans in the Southwest US (ASW) population. 28 While no categorization will result in 199 perfect prediction, given the spectrum of human diversity, the statistical validation of this 200 clustering from broad autosomal data makes these clusters both relevant and useful for 201
PharmGKB. 202 10 In Figure 3 , we demonstrate that the groups we have selected are effective for 203 representing the diversity of global allele frequencies in pharmacogenes. We present here the 204 frequency of four single nucleotide polymorphisms (SNPs) with important pharmacogenetic 205 implications. The 'A' allele of rs1065852 is the defining SNP of the cytochrome P450 2D6 206 (CYP2D6) *10 haplotype and is also found in combination with other variants in multiple 207 CYP2D6 haplotypes. Haplotypes containing this SNP are associated with decreased CYP2D6 208 activity, which has important implications for drugs that are CYP2D6 substrates, including 209 codeine, selective serotonin reuptake inhibitors, ondansetron, and tricyclic antidepressants. 29-31 210 The CYP2C9 alleles *2 (defined by rs1799853), *3 (defined by rs1057910), and *8 (defined by 211 rs7900194) are associated with reduced enzyme function and therefore are associated with 212 recommended changes to the dosing of warfarin and phenytoin, which are substrates of 213 CYP2C9. 32; 33 Using data from the 1000 Genomes, we show the frequency of the four SNPs in 214 these biogeographic groups. The range of frequencies globally illustrates the importance of 215 showing allele frequency by group in order to convey its impact on drug response globally. 216
The SNP rs1065852 shows stark continental patterns (Figure 3A) . The 'A' allele is found 217 at high frequencies within East Asian populations, ranging from 66.2% in Vietnam (KHV) to 218 36.1% in Japan (JPT). This allele is less frequent in other continental populations, such as Africa 219
(3.5-16.5%), Europe (14.6-24.7%), and South Asia (10.4-25.6%). As can be seen from the range 220 of frequencies of the three CYP2C9 alleles, the most common reduced function allele varies 221 globally, with the *8 allele much more common in African populations (1.8-7.6%) than the *2 222 (<1%) or *3 (monomorphic in Africa) (Figure 3B-D) . Conversely, the *8 allele is rare in 223
European populations (<1%), while *2 (8.1-15.2%) and *3 (5.6-8.4%) are more common. research. 19 However, the groups we present are large and the summary information presented 235 should be understood as an approximation dependent on existing studies in that region, which 236 may be limited to a few locations. As such, these groups are not suitable for use in guiding 237 specific implementation programs; rather, they should be seen as a tool for research purposes. 238
It should be noted that this grouping system does have some limitations. Classifying 239 individuals into these population groups can be complicated by social and cultural identities, 240 especially for admixed individuals, 7; 9; 37-39 and membership of an individual within one of these 241 population groups is inherently an imperfect surrogate for predicting the likelihood that the 242 individual carries a particular genetic variant. 36; 40 As can be seen in the analysis of rs1065852 243 above, the frequency of the 'A' allele can vary by up to 30% between populations which are all 244 included in the East Asian group. Furthermore, while the grouping system is based on overall 245 genome-wide average patterns, which typically follow a clinal variation pattern correlated with 246 geographic proximity, 7; 22; 23; 41; 42 variation in individual genes or individual populations do not 247 always follow these gradual patterns. 8-11; 36 248 12 Because aggregate annotations of pharmacogenetic research and summary allele 249 frequencies are based only on available studies, additional studies are needed that include a 250 greater diversity of populations to make pharmacogenetic research and allele frequency 251 summaries more representative. 43 For example, the Sub-Saharan Africa (SSA) grouping 252 represents a large swath of human genomic diversity, and increased representation of these 253 populations in pharmacogenetics studies may lead to the discovery of clinical differences within 254 the larger grouping. Furthermore, large, reference genetic studies with targeted allele 255 information, like that emerging from the Population Architecture using Genomics and 256 Epidemiology (PAGE) study (www.pagestudy.org), may provide compelling evidence to adjust 257 these group boundaries based on frequency patterns specific to pharmacogenetic alleles. 258
Despite these limitations, broad population groups are needed for illustrating global 259 diversity with respect to pharmacogenetic variation and the average predicted phenotypes in 260 populations. These nine proposed biogeographic groups provide a consistent way to present 261 these data based on a system that is grounded in robust data on population genetic patterns. 262
PharmGKB has begun to use these population groups in curation activities, and we recommend 263 that these groups and accompanying map be considered the standard grouping mechanism for 264 population pharmacogenetics. Ultimately, individual pharmacogenetic testing of all patients, 265 regardless of ancestry, is needed to deliver truly personalized medicine. However, the population 266 groups we present are useful for the standardized presentation of pharmacogenetic studies, global 267 allele frequency summaries in pharmacogenetic research and broad clinical screening. showing high degree of population structure. Note that, because none of the 1000 Genomes 437 populations fall into the American (AME) group, no reference data were available to include this 438 group in the analysis. 439 
